Email
IZ Express #1,644: Immunize.org summarizes July 19 ACIP meeting on Novavax COVID-19 Vaccine for adults
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,644: Immunize.org summarizes July 19 ACIP meeting on Novavax COVID-19 Vaccine for adults |
| Date | July 27, 2022 10:00 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed] [link removed] [link removed] [link removed] [link removed]
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,644: July 27, 2022
Top Stories
* Immunize.org summarizes ACIP’s July 19 meeting recommending use of Novavax COVID-19 Vaccine for adults age 18 years and older
* HHS and CDC offer July 29 webinar for parents, caregivers, and community partners on COVID-19 vaccination for children age 6 months and over
* National Immunization Awareness Month starts August 1; promote vaccination with CDC resources
* Immunize.org updates its two guides to contraindications and precautions for commonly used vaccines
* Immunize.org updates “Healthcare Personnel Vaccination Recommendations” resource for staff
* Spotlight: Immunize.org’s “Clinic Tools” main page is a one-stop source of practical information for vaccines
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Pages and Handouts
* Recap: These updated Immunize.org educational materials and web pages for clinicians were released during June and July
Vaccine Information Statements
* Recap: These new VISs and VIS translations were released during June and July
Featured Resources
* Novavax COVID-19 Vaccine EUA factsheets for recipients and caregivers are now available in 12 languages
* Recognize colleagues and students with Immunize.org's elegantly designed "Vaccines Save Lives" black enamel pins
Notable Publications
* “Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022” published in MMWR
* “Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022” published in MMWR
* “Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season” published in MMWR
* “Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022” published in MMWR
Upcoming Events
* Virtual: HHS and CDC offer webinar "Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners" on July 29
* On-demand: CDC’s recorded webinars on principles of vaccination and general best practice guidelines, as well as other segments in “The Pink Book,” now rolling out weekly; CE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org summarizes ACIP’s July 19 meeting recommending use of Novavax COVID-19 Vaccine for adults age 18 years and older
The Advisory Committee on Immunization Practices (ACIP) ([link removed]) met on July 19, 2022 ([link removed]) and recommended use of Novavax COVID-19 Vaccine as a two-dose primary series in adults age 18 years and older. The ACIP recommendation followed the FDA’s July 13 Emergency Use Authorization (EUA) ([link removed]) for the vaccine. The Novavax vaccine joins others from Pfizer-BioNTech, Moderna, and Janssen as the fourth COVID-19 vaccine to receive EUA status and a CDC recommendation ([link removed]) . Presentation slides ([link removed]) from the meeting are available online. Basic information on this vaccine follows.
Vaccine platform: The Novavax vaccine is an adjuvanted protein subunit vaccine. It contains a small quantity (5 mcg) of manufactured spike protein that imitates the natural spike protein on the SARS-CoV-2 virus, combined with a saponin-derived adjuvant (Matrix-M). The adjuvant enhances the immune response to the vaccine. Protein subunit vaccines are common and have been used in the United States for decades.
Indications for use: The Novavax vaccine is administered intramuscularly (IM) in the deltoid muscle as a primary series of two 0.5 mL doses given 3 to 8 weeks apart.* At this time, it is not authorized for use as a booster dose.
*An interval of up to 8 weeks may enhance the immune response and may reduce the risk of myocarditis after dose 2, compared to a 3-week interval. A 3-week interval remains preferred for people age 65 years or older, immunocompromised people, and others in circumstances where rapid protection is needed.
Clinical considerations: CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States ([link removed]) should be carefully reviewed by all vaccinators for details on vaccine use. Highlights related to the Novavax vaccine include:
* Reactogenicity: During clinical trials, pain or tenderness at the injection site was the most frequently reported local reaction, with redness and swelling reported less frequently. Fatigue, headache, and muscle pain were the most commonly reported systemic reactions. Most symptoms were mild to moderate in severity and resolved within 1–3 days. Overall, symptoms were more frequent in adults younger than age 65 compared to those 65 years and older and were more likely to occur after the second dose.
* Immunocompromising conditions: Currently, people who are moderately or severely immunocompromised are recommended to receive the same 2-dose schedule of Novavax vaccine as the general population. No additional dose is recommended.
* Coadministration with other vaccines: In general, COVID-19 vaccines (including the Novavax vaccine) may be administered without regard to timing of other vaccines. However, CDC now advises vaccinators to consider deferring COVID-19 vaccination up to 4 weeks after orthopoxvirus vaccination of individuals affected by the ongoing monkeypox outbreak. When urgent protection from monkeypox is indicated for a recent COVID-19 vaccine recipient, orthopoxvirus vaccination should not be delayed.
* Contraindications and precautions: The Novavax vaccine is contraindicated in people with a history of a severe allergic reaction after a previous dose or a diagnosed allergy to any vaccine component, such as polysorbate.
Vaccine safety: A small number of cases of myocarditis were identified during the clinical trials and additional cases have been identified in post-marketing safety data from countries where the Novavax vaccine is already in widespread use. After reviewing the available data, ACIP determined that the risk of this rare occurrence was outweighed by the benefits provided by vaccination, especially in light of evidence that the risk of myocarditis and other heart problems is much higher following COVID-19 infection than after COVID-19 vaccination. No anaphylactic reactions or thrombosis with thrombocytopenia (TTS) were reported during the trials.
Although pregnant individuals were excluded from participation in the Novavax vaccine clinical trials, some participants became pregnant or their pregnancy was detected after vaccination. The limited data available from these participants did not indicate adverse effects on mother or fetus. Novavax established a pregnancy exposure registry ([link removed]) to continue to study the effects of vaccination during pregnancy.
Storage and handling: The vaccine is supplied in 10-dose vials in cartons of 10 vials each. It is maintained at standard refrigeration temperatures of 2° to 8° C (36° to 46° F) and must not be frozen.
Once punctured, the preservative-free multidose vial may be refrigerated or kept at room temperature (2° to 25°C [36° to 77° F] for up to 6 hours. Any vaccine remaining after 6 hours must be discarded. The expiration date is not printed on the vial or carton: users must check the “Expiry Date Checker Tool” at the Novavax website ([link removed]) to determine the expiration date of an unopened vial.
Anticipated demand: Adding this adjuvanted protein subunit vaccine as a choice for primary vaccination against COVID-19 to the previously authorized vaccines offers a valuable new option for previously unvaccinated people. Approximately 26–37 million US adults remain unvaccinated against COVID-19. Some have not been vaccinated because of hesitancy about currently available products developed using newer technology. In an unpublished survey (CDC and University of Iowa/RAND), 16% of unvaccinated respondents indicated they “probably” or “definitely” would accept an available adjuvanted protein-based COVID-19 vaccine that was manufactured using traditional technology common to other routine vaccines. Because the Novavax vaccine is not authorized as a booster dose at this time, initial uptake is expected to be limited.
Vaccine effectiveness: Clinical trials demonstrated that the Novavax vaccine was highly effective at preventing moderate or severe COVID-19 illness caused by the variants circulating at the time. Because the clinical trials took place well before the emergence of Omicron variants, the effectiveness of the vaccine against the SARS-CoV-2 variants circulating today is not known. Limited studies of antibodies from the serum of Novavax vaccine recipients suggest that vaccination is likely to show good effectiveness against severe disease caused by current variants, as the other authorized vaccines do.
In addition to the Novavax vaccine discussion, ACIP members received an update on current COVID-19 epidemiology and vaccine coverage in the United States, as well as a review of vaccine-associated myocarditis. There were no significant new findings since the update in June 2022.
The next scheduled ACIP meeting will be held on October 19–20, 2022, although additional emergency meetings may be announced prior to that time. Information about past and future ACIP meetings ([link removed]) may be found on the ACIP website.
Related Links
* ACIP main page ([link removed]) for content from previous meetings, as well as information about future meetings
* CDC: ACIP Presentation Slides ([link removed]) : July 19 Meeting web page
* CDC: Interim Clinical Considerations: Summary of Recent Changes for use of COVID-19 vaccines in the United States ([link removed]) main page
* FDA: Fact Sheet for Healthcare Providers Administering Vaccine: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (7/13/2022)
* FDA: Fact Sheet for Recipients and Caregivers: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (7/13/2022)
* CDC: At-a-Glance: COVID-19 Vaccination Schedules ([link removed])
* CDC: COVID-19: Novavax ([link removed]) , adjuvanted vaccine, overview, and safety web page (information for the general public)
------------------------------------------------------------
HHS and CDC offer July 29 webinar for parents, caregivers, and community partners on COVID-19 vaccination for children age 6 months and over
The U.S. Department of Health and Human Services (HHS), Office of Minority Health (OMH), and CDC Office of Minority Health and Health Equity (OMHHE) will host a webinar titled Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) from 1:30–3:00 p.m. (ET) on July 29. Speakers include pediatric vaccine experts from HHS, CDC, and community partners leading vaccine efforts for children and youth. Webinar attendees will learn the latest information on:
* CDC’s COVID-19 vaccination recommendations for everyone age 6 months and older
* Where to find resources and credible information on vaccine safety
* The risks, benefits, and myths associated with COVID-19 vaccinations for children and youth
* What to ask a health provider about COVID-19 vaccination if your child has a disability
* How community partners are working to protect Black/African American, Hispanic/Latino, American Indian/Alaska Native, Asian American, and Native Hawaiian/Pacific Islander children and youth with disabilities who live in communities disproportionately impacted by COVID-19
Register for the webinar ([link removed]) .
For questions about the webinar, please contact CDC’s Office of Minority Health and Health Equity at [email protected] (mailto:[email protected]) .
[link removed]
CDC also offers communication resources ([link removed]) and printable fact sheets ([link removed]) in six languages for the webinar that can be distributed widely. Please use #ProtectChildren along with CDC's social media messages and images ([link removed]) to share information across your social media
channels.
For more information on COVID-19 vaccination for children and youth, please visit the Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) web page.
Back to top (#Top)
------------------------------------------------------------
National Immunization Awareness Month starts August 1; promote vaccination with CDC resources
August is National Immunization Awareness Month ([link removed]) (NIAM). This annual observance highlights the efforts to protect people of all ages against vaccine-preventable diseases through on-time vaccination. This year, NIAM serves as an important reminder to catch up on routine visits and vaccinations that may have been disrupted by the COVID-19 pandemic.
During NIAM, encourage your patients to schedule appointments to ensure they are up to date on annual exams and recommended vaccines. Research shows that healthcare providers are the most trusted source of vaccine information for parents and patients.
[link removed]
CDC’s NIAM web page includes two toolkits, one for reaching healthcare professionals ([link removed]) and the other for reaching parents and patients ([link removed]) . Each includes key messages, sample social media content, and educational resources. CDC encourages its partners to share these messages and resources throughout August using the hashtag #ivax2protect. Stay tuned for more resources to be released throughout the coming weeks.
Related Links
* CDC: Toolkit for Reaching Healthcare Professionals ([link removed]) main page
* CDC: Toolkit for Reaching Parents and Patients ([link removed]) main page
------------------------------------------------------------
Immunize.org updates its two guides to contraindications and precautions for commonly used vaccines
Immunize.org recently updated Guide to Contraindications and Precautions to Commonly Used Vaccines in Adults ([link removed]) , which is based on the version found in the 2022 "Recommended Immunization Schedule for Adults." The Immunize.org guide adds more detail for the category of "Not Recommended" to address the ACIP guidance for two HepB vaccine products and HPV vaccination during pregnancy.
Immunize.org also updated Guide to Contraindications and Precautions to Commonly Used Vaccines for All Ages ([link removed]) , which is based on the versions found in both the 2022 "Recommended Immunization Schedule for Children and Adolescents" and "Recommended Immunization Schedule for Adults." The Immunize.org guide adds more detail for the category of "Not Recommended" to address the ACIP guidance for two HepB vaccine products and HPV vaccination during pregnancy.
[link removed] [link removed]
Related Links
* Immunize.org: Handouts: Contraindications and Precautions ([link removed]) main page
* Immunize.org: Handouts: Schedules for Patients ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates “Healthcare Personnel Vaccination Recommendations” resource for staff
Immunize.org updated its 1-page guide Healthcare Personnel Vaccination Recommendations ([link removed]) to include both Twinrix and PreHevbrio as HepB vaccine options, and to include a recommendation for a third dose of MMR for healthcare personnel who are identified by public health authorities to be at increased risk for mumps during an outbreak.
[link removed]
Related Links
* Immunize.org: Handouts: Vaccine Recommendation ([link removed]) main page
* Immunize.org: Handouts: Healthcare Personnel ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org’s “Clinic Tools” main page is a one-stop source of practical information for vaccines
Immunize.org's Clinic Tools main page ([link removed]) compiles resources from Immunize.org, CDC, and other organizations containing practical, “how-to” information about providing vaccinations in a medical office or non-traditional setting. This page can be found by selecting the “Clinic Tools” tab in the middle of the blue banner atop every Immunize.org web page
In the left-hand column, you will find links to Immunize.org’s web pages:
* Immunize.org: Clinic Tools ([link removed]) main page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed])
* Immunize.org: Clinic Tools: Adolescent Vaccination ([link removed])
* Immunize.org: Clinic Tools: Adult Vaccination ([link removed])
* Immunize.org: Clinic Tools: Documenting Vaccinations ([link removed])
* Immunize.org: Clinic Tools: Scheduling Vaccines ([link removed])
* Immunize.org: Clinic Tools: Screening for Vaccine Contraindications and Precautions ([link removed])
* Immunize.org: Clinic Tools: Storage and Handling ([link removed])
* Immunize.org: Clinic Tools: Vaccination and COVID-19 ([link removed])
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed])
[link removed]
The right-hand column features resources from partners, including CDC’s vaccine recommendations, “General Best Practice Guidelines for Immunization,” and The Epidemiology and Prevention of Vaccine-Preventable Diseases (“The Pink Book”).
Visit the Clinic Tools main page ([link removed]) on Immunize.org.
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is one of our recent citations.
* Washington Post Coronavirus Updates newsletter: Your Questions, Answered ([link removed]) section (7/18/22)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* STAT: WHO Declared Monkeypox Outbreak a Public Health Emergency ([link removed]) (7/23/22)
* ABC: Many Unvaccinated First Responders Distrust Vaccine, Study Says ([link removed]) (7/19/22)
* New York Times: For Monkeypox Patients, Excruciating Symptoms and a Struggle for Care ([link removed]) (7/18/22)
* CNN: India Hits 2 Billion COVID-19 Vaccinations as Infections Hit Four-Month High ([link removed]) (7/17/22)
* New York Times: Sharp Drop in Childhood Vaccinations Threatens Millions of Lives ([link removed]) (7/14/22)
* CNN: Demand for Monkeypox Vaccine Rises with Case Counts, but Supply Remains Low ([link removed]) (7/14/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Recap: These updated Immunize.org educational materials and web pages for clinicians were released during June and July
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials and web pages. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Updated Printable Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (7/8/22)
* Summary of Recommendations for Adult Immunization (age 19 years and older) ([link removed])
* Summary of Recommendations for Child/Teen Immunization (age birth through 18 years) ([link removed])
* Standing Orders for Administering Inactivated Poliovirus Vaccine to Children and Teens ([link removed])
* Standing Orders for Administering Human Papillomavirus Vaccine to Children and Teens ([link removed])
* Emergency Response Worksheet ([link removed])
Immunize.org Updated Web Pages
* Vaccines: COVID-19 ([link removed])
Immunize.org Updated Printable Materials for Patients
* Vaccinations Needed During Pregnancy ([link removed])
* Vaccinations for Adults with Chronic Liver Disease or Infection ([link removed])
* Vaccinations for Adults with Diabetes ([link removed])
* Vaccinations for Adults with Heart Disease ([link removed])
* Vaccinations for Adults with Lung Disease ([link removed])
* Vaccinations for Adults with HIV infection ([link removed])
* Vaccinations for Adults without a Spleen ([link removed])
* Vaccinations for Men Who Have Sex with Men ([link removed])
* Human Papillomavirus (HPV): A Parent’s Guide to Preteen and Teen HPV Vaccination ([link removed])
* Seven translations (Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Spanish ([link removed]) , and Vietnamese ([link removed]) ) were provided for both of these updated handouts for parents:
+ When Do Children and Teens Need Vaccinations? ([link removed])
+ Vaccinations for Preteens and Teens ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,400 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its nine subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: These new VISs and VIS translations were released during June and July
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
In June, CDC released three VISs:
* Ebola vaccine VIS ([link removed])
* Rabies vaccine VIS ([link removed])
* Smallpox/Monkeypox vaccine VIS ([link removed])
Here are recent VIS translations posted during June and July:
* Hepatitis A vaccine VIS ([link removed]) - Ukrainian
* Hepatitis B vaccine VIS ([link removed]) - Ukrainian
* Influenza (inactive ([link removed]) ) vaccine VIS - Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai
* Influenza (live) ([link removed]) vaccine VIS – Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai
* MMR vaccine VIS - ([link removed]) Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai, Ukrainian
* Polio vaccine VIS ([link removed]) - Ukrainian
* Smallpox/Monkeypox vaccine VIS ([link removed]) - Spanish
* Tdap vaccine VIS ([link removed]) - Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai, Ukrainian
* Varicella (chickenpox) vaccine VIS ([link removed]) - Ukrainian
Additionally, two handouts related to VISs were updated:
* Dates of Current Vaccine Information Statements (VISs) ([link removed])
* You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law! ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Novavax COVID-19 Vaccine EUA factsheets for recipients and caregivers are now available in 12 languages
The Novavax COVID-19 Vaccine received Emergency Use Authorization (EUA) from the FDA to provide a two-dose primary series to individuals age 18 and older. The Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Recipients and Caregivers ([link removed]) is now available in 12 languages, courtesy of Oregon Immunization Program. The languages include:
* Arabic ([link removed])
* Chinese – Simplified ([link removed])
* Chinese – Traditional ([link removed])
* Chuukese ([link removed])
* English ([link removed])
* Hmong ([link removed])
* Korean ([link removed])
* Marshallese ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish ([link removed])
* Vietnamese ([link removed])
Related Links
* FDA: Fact Sheet for Healthcare Providers Administering Vaccine: Novavax COVID-19 Vaccine, Adjuvanted ([link removed])
* CDC: Novavax COVID-19, Adjuvanted Vaccine: Overview and Safety ([link removed]) web page (information for the general public)
------------------------------------------------------------
Recognize colleagues and students with Immunize.org's elegantly designed "Vaccines Save Lives" black enamel pins
Immunize.org’s elegantly designed “Vaccines Save Lives” pins ([link removed]) are meaningful gifts for people who care about vaccination. The pin makes a refined statement in hard black enamel with gold lettering and edges, measuring 1.125" x 0.75".
[link removed]
The pin is a stick-through-post variety with the back end covered by a round rubber cap that holds the pin securely. A gold metal spring-lock clasp is also provided.
Wear these pins on clothing, ([link removed]) uniforms, and white coats to show that you value vaccines.
([link removed])
Click here for "Vaccines Save Lives" pin pricing and ordering information. ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022” published in MMWR
CDC published Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
The COVID-19 pandemic has strained many essential frontline professionals, including public health workers....
The 2021 Public Health Workforce Interests and Needs Survey recorded the perspectives of the governmental public health workforce. During March 2020–January 2022, 72% of the workforce fully or partially served in a COVID-19 response role. Apart from funding, 51% of respondents cited a need for additional staff capacity to respond to COVID-19. Approximately 40% of the workforce intends to leave their jobs within the next 5 years....
Purposeful succession planning and focused attention on recruitment and retention that promotes diversity will be critical as the workforce rebuilds while the COVID-19 pandemic evolves.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022” published in MMWR
CDC published Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
In 2021, state, tribal, local, and territorial (STLT) public health workers reported high levels of symptoms of at least one mental health condition (depression, anxiety, or posttraumatic stress disorder [PTSD])....
In a 2022 survey of 26,069 STLT public health workers, higher PTSD prevalence was associated with more weekly work hours and more time spent on COVID-19 response activities. Most (75.5%) respondents did not think their employer increased mental health support....
To support the mental health of public health workers, public health agencies can modify work-related factors, including making organizational changes for emergency responses and facilitating access to mental health resources and services.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season” published in MMWR
CDC published Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
CDC collects, compiles, and analyzes data on U.S. influenza activity and viruses....
The severity of the 2021–22 influenza season was low, with two waves of influenza A activity. Influenza activity continued from October 2021 through mid-June 2022, with A(H3N2) viruses predominating throughout the season. This report also describes the composition of the Northern Hemisphere 2022–23 influenza vaccine....
Because of the atypical timing and duration of influenza activity, providers and patients should consider influenza infection as a cause of respiratory illness. Testing for seasonal influenza and monitoring for novel viruses, especially avian A(H5N1) and swine viruses, should continue year-round. Receiving a seasonal influenza vaccine each year remains the best way to protect against seasonal influenza and its potentially severe consequences.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022” published in MMWR
CDC published Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
Little is known about COVID-19 vaccine effectiveness (VE) during the Omicron variant BA.2/BA.2.12.2–predominant period or VE of a fourth COVID-19 vaccine dose in persons aged ≥50 years....
VE during the BA.2/BA.2.12.2 period was lower than that during the BA.1 period. A third vaccine dose provided additional protection against moderate and severe COVID-19–associated illness in all age groups, and a fourth dose provided additional protection in eligible adults aged ≥50 years....
Immunocompetent persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19, including a first booster dose for all eligible persons and second dose for adults aged ≥50 years at least 4 months after an initial booster dose. Booster doses should be obtained immediately when persons become eligible.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: HHS, OMH, and CDC offer webinar "Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners" on July 29
As described in detail in today’s Top Stories above, the U.S. Department of Health and Human Services (HHS), Office of Minority Health (OMH), and CDC Office of Minority Health and Health Equity (OMHHE) will host a webinar titled Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) from 1:30–3:00 p.m. (ET) on July 29.
Register for the webinar ([link removed]) . Share this opportunity with interested parents and community members.
For questions about the webinar, please contact CDC’s Office of Minority Health and Health Equity at [email protected] (mailto:[email protected]) .
------------------------------------------------------------
On-demand: CDC’s recorded webinars on principles of vaccination and general best practice guidelines, as well as other segments in “The Pink Book,” now rolling out weekly; CE available
CDC continues its 19-part pre-recorded webinar series ([link removed]) to provide a chapter-by-chapter overview of the 14th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases ([link removed]) (also known as "The Pink Book").
The fourth webinar, on immunization strategies, was released on July 26; no registration is required. Additional webinars will be released weekly, concluding on November 1, 2022.
Information and program details are available on CDC's Pink Book Webinars series ([link removed]) web page.
CME, CNE, CPE, and CEU credits are available for each event. Questions about the material can be submitted to [email protected] (mailto:[email protected]) .
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,644: July 27, 2022
Top Stories
* Immunize.org summarizes ACIP’s July 19 meeting recommending use of Novavax COVID-19 Vaccine for adults age 18 years and older
* HHS and CDC offer July 29 webinar for parents, caregivers, and community partners on COVID-19 vaccination for children age 6 months and over
* National Immunization Awareness Month starts August 1; promote vaccination with CDC resources
* Immunize.org updates its two guides to contraindications and precautions for commonly used vaccines
* Immunize.org updates “Healthcare Personnel Vaccination Recommendations” resource for staff
* Spotlight: Immunize.org’s “Clinic Tools” main page is a one-stop source of practical information for vaccines
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Pages and Handouts
* Recap: These updated Immunize.org educational materials and web pages for clinicians were released during June and July
Vaccine Information Statements
* Recap: These new VISs and VIS translations were released during June and July
Featured Resources
* Novavax COVID-19 Vaccine EUA factsheets for recipients and caregivers are now available in 12 languages
* Recognize colleagues and students with Immunize.org's elegantly designed "Vaccines Save Lives" black enamel pins
Notable Publications
* “Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022” published in MMWR
* “Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022” published in MMWR
* “Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season” published in MMWR
* “Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022” published in MMWR
Upcoming Events
* Virtual: HHS and CDC offer webinar "Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners" on July 29
* On-demand: CDC’s recorded webinars on principles of vaccination and general best practice guidelines, as well as other segments in “The Pink Book,” now rolling out weekly; CE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org summarizes ACIP’s July 19 meeting recommending use of Novavax COVID-19 Vaccine for adults age 18 years and older
The Advisory Committee on Immunization Practices (ACIP) ([link removed]) met on July 19, 2022 ([link removed]) and recommended use of Novavax COVID-19 Vaccine as a two-dose primary series in adults age 18 years and older. The ACIP recommendation followed the FDA’s July 13 Emergency Use Authorization (EUA) ([link removed]) for the vaccine. The Novavax vaccine joins others from Pfizer-BioNTech, Moderna, and Janssen as the fourth COVID-19 vaccine to receive EUA status and a CDC recommendation ([link removed]) . Presentation slides ([link removed]) from the meeting are available online. Basic information on this vaccine follows.
Vaccine platform: The Novavax vaccine is an adjuvanted protein subunit vaccine. It contains a small quantity (5 mcg) of manufactured spike protein that imitates the natural spike protein on the SARS-CoV-2 virus, combined with a saponin-derived adjuvant (Matrix-M). The adjuvant enhances the immune response to the vaccine. Protein subunit vaccines are common and have been used in the United States for decades.
Indications for use: The Novavax vaccine is administered intramuscularly (IM) in the deltoid muscle as a primary series of two 0.5 mL doses given 3 to 8 weeks apart.* At this time, it is not authorized for use as a booster dose.
*An interval of up to 8 weeks may enhance the immune response and may reduce the risk of myocarditis after dose 2, compared to a 3-week interval. A 3-week interval remains preferred for people age 65 years or older, immunocompromised people, and others in circumstances where rapid protection is needed.
Clinical considerations: CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States ([link removed]) should be carefully reviewed by all vaccinators for details on vaccine use. Highlights related to the Novavax vaccine include:
* Reactogenicity: During clinical trials, pain or tenderness at the injection site was the most frequently reported local reaction, with redness and swelling reported less frequently. Fatigue, headache, and muscle pain were the most commonly reported systemic reactions. Most symptoms were mild to moderate in severity and resolved within 1–3 days. Overall, symptoms were more frequent in adults younger than age 65 compared to those 65 years and older and were more likely to occur after the second dose.
* Immunocompromising conditions: Currently, people who are moderately or severely immunocompromised are recommended to receive the same 2-dose schedule of Novavax vaccine as the general population. No additional dose is recommended.
* Coadministration with other vaccines: In general, COVID-19 vaccines (including the Novavax vaccine) may be administered without regard to timing of other vaccines. However, CDC now advises vaccinators to consider deferring COVID-19 vaccination up to 4 weeks after orthopoxvirus vaccination of individuals affected by the ongoing monkeypox outbreak. When urgent protection from monkeypox is indicated for a recent COVID-19 vaccine recipient, orthopoxvirus vaccination should not be delayed.
* Contraindications and precautions: The Novavax vaccine is contraindicated in people with a history of a severe allergic reaction after a previous dose or a diagnosed allergy to any vaccine component, such as polysorbate.
Vaccine safety: A small number of cases of myocarditis were identified during the clinical trials and additional cases have been identified in post-marketing safety data from countries where the Novavax vaccine is already in widespread use. After reviewing the available data, ACIP determined that the risk of this rare occurrence was outweighed by the benefits provided by vaccination, especially in light of evidence that the risk of myocarditis and other heart problems is much higher following COVID-19 infection than after COVID-19 vaccination. No anaphylactic reactions or thrombosis with thrombocytopenia (TTS) were reported during the trials.
Although pregnant individuals were excluded from participation in the Novavax vaccine clinical trials, some participants became pregnant or their pregnancy was detected after vaccination. The limited data available from these participants did not indicate adverse effects on mother or fetus. Novavax established a pregnancy exposure registry ([link removed]) to continue to study the effects of vaccination during pregnancy.
Storage and handling: The vaccine is supplied in 10-dose vials in cartons of 10 vials each. It is maintained at standard refrigeration temperatures of 2° to 8° C (36° to 46° F) and must not be frozen.
Once punctured, the preservative-free multidose vial may be refrigerated or kept at room temperature (2° to 25°C [36° to 77° F] for up to 6 hours. Any vaccine remaining after 6 hours must be discarded. The expiration date is not printed on the vial or carton: users must check the “Expiry Date Checker Tool” at the Novavax website ([link removed]) to determine the expiration date of an unopened vial.
Anticipated demand: Adding this adjuvanted protein subunit vaccine as a choice for primary vaccination against COVID-19 to the previously authorized vaccines offers a valuable new option for previously unvaccinated people. Approximately 26–37 million US adults remain unvaccinated against COVID-19. Some have not been vaccinated because of hesitancy about currently available products developed using newer technology. In an unpublished survey (CDC and University of Iowa/RAND), 16% of unvaccinated respondents indicated they “probably” or “definitely” would accept an available adjuvanted protein-based COVID-19 vaccine that was manufactured using traditional technology common to other routine vaccines. Because the Novavax vaccine is not authorized as a booster dose at this time, initial uptake is expected to be limited.
Vaccine effectiveness: Clinical trials demonstrated that the Novavax vaccine was highly effective at preventing moderate or severe COVID-19 illness caused by the variants circulating at the time. Because the clinical trials took place well before the emergence of Omicron variants, the effectiveness of the vaccine against the SARS-CoV-2 variants circulating today is not known. Limited studies of antibodies from the serum of Novavax vaccine recipients suggest that vaccination is likely to show good effectiveness against severe disease caused by current variants, as the other authorized vaccines do.
In addition to the Novavax vaccine discussion, ACIP members received an update on current COVID-19 epidemiology and vaccine coverage in the United States, as well as a review of vaccine-associated myocarditis. There were no significant new findings since the update in June 2022.
The next scheduled ACIP meeting will be held on October 19–20, 2022, although additional emergency meetings may be announced prior to that time. Information about past and future ACIP meetings ([link removed]) may be found on the ACIP website.
Related Links
* ACIP main page ([link removed]) for content from previous meetings, as well as information about future meetings
* CDC: ACIP Presentation Slides ([link removed]) : July 19 Meeting web page
* CDC: Interim Clinical Considerations: Summary of Recent Changes for use of COVID-19 vaccines in the United States ([link removed]) main page
* FDA: Fact Sheet for Healthcare Providers Administering Vaccine: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (7/13/2022)
* FDA: Fact Sheet for Recipients and Caregivers: Novavax COVID-19 Vaccine, Adjuvanted ([link removed]) (7/13/2022)
* CDC: At-a-Glance: COVID-19 Vaccination Schedules ([link removed])
* CDC: COVID-19: Novavax ([link removed]) , adjuvanted vaccine, overview, and safety web page (information for the general public)
------------------------------------------------------------
HHS and CDC offer July 29 webinar for parents, caregivers, and community partners on COVID-19 vaccination for children age 6 months and over
The U.S. Department of Health and Human Services (HHS), Office of Minority Health (OMH), and CDC Office of Minority Health and Health Equity (OMHHE) will host a webinar titled Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) from 1:30–3:00 p.m. (ET) on July 29. Speakers include pediatric vaccine experts from HHS, CDC, and community partners leading vaccine efforts for children and youth. Webinar attendees will learn the latest information on:
* CDC’s COVID-19 vaccination recommendations for everyone age 6 months and older
* Where to find resources and credible information on vaccine safety
* The risks, benefits, and myths associated with COVID-19 vaccinations for children and youth
* What to ask a health provider about COVID-19 vaccination if your child has a disability
* How community partners are working to protect Black/African American, Hispanic/Latino, American Indian/Alaska Native, Asian American, and Native Hawaiian/Pacific Islander children and youth with disabilities who live in communities disproportionately impacted by COVID-19
Register for the webinar ([link removed]) .
For questions about the webinar, please contact CDC’s Office of Minority Health and Health Equity at [email protected] (mailto:[email protected]) .
[link removed]
CDC also offers communication resources ([link removed]) and printable fact sheets ([link removed]) in six languages for the webinar that can be distributed widely. Please use #ProtectChildren along with CDC's social media messages and images ([link removed]) to share information across your social media
channels.
For more information on COVID-19 vaccination for children and youth, please visit the Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) web page.
Back to top (#Top)
------------------------------------------------------------
National Immunization Awareness Month starts August 1; promote vaccination with CDC resources
August is National Immunization Awareness Month ([link removed]) (NIAM). This annual observance highlights the efforts to protect people of all ages against vaccine-preventable diseases through on-time vaccination. This year, NIAM serves as an important reminder to catch up on routine visits and vaccinations that may have been disrupted by the COVID-19 pandemic.
During NIAM, encourage your patients to schedule appointments to ensure they are up to date on annual exams and recommended vaccines. Research shows that healthcare providers are the most trusted source of vaccine information for parents and patients.
[link removed]
CDC’s NIAM web page includes two toolkits, one for reaching healthcare professionals ([link removed]) and the other for reaching parents and patients ([link removed]) . Each includes key messages, sample social media content, and educational resources. CDC encourages its partners to share these messages and resources throughout August using the hashtag #ivax2protect. Stay tuned for more resources to be released throughout the coming weeks.
Related Links
* CDC: Toolkit for Reaching Healthcare Professionals ([link removed]) main page
* CDC: Toolkit for Reaching Parents and Patients ([link removed]) main page
------------------------------------------------------------
Immunize.org updates its two guides to contraindications and precautions for commonly used vaccines
Immunize.org recently updated Guide to Contraindications and Precautions to Commonly Used Vaccines in Adults ([link removed]) , which is based on the version found in the 2022 "Recommended Immunization Schedule for Adults." The Immunize.org guide adds more detail for the category of "Not Recommended" to address the ACIP guidance for two HepB vaccine products and HPV vaccination during pregnancy.
Immunize.org also updated Guide to Contraindications and Precautions to Commonly Used Vaccines for All Ages ([link removed]) , which is based on the versions found in both the 2022 "Recommended Immunization Schedule for Children and Adolescents" and "Recommended Immunization Schedule for Adults." The Immunize.org guide adds more detail for the category of "Not Recommended" to address the ACIP guidance for two HepB vaccine products and HPV vaccination during pregnancy.
[link removed] [link removed]
Related Links
* Immunize.org: Handouts: Contraindications and Precautions ([link removed]) main page
* Immunize.org: Handouts: Schedules for Patients ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates “Healthcare Personnel Vaccination Recommendations” resource for staff
Immunize.org updated its 1-page guide Healthcare Personnel Vaccination Recommendations ([link removed]) to include both Twinrix and PreHevbrio as HepB vaccine options, and to include a recommendation for a third dose of MMR for healthcare personnel who are identified by public health authorities to be at increased risk for mumps during an outbreak.
[link removed]
Related Links
* Immunize.org: Handouts: Vaccine Recommendation ([link removed]) main page
* Immunize.org: Handouts: Healthcare Personnel ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org’s “Clinic Tools” main page is a one-stop source of practical information for vaccines
Immunize.org's Clinic Tools main page ([link removed]) compiles resources from Immunize.org, CDC, and other organizations containing practical, “how-to” information about providing vaccinations in a medical office or non-traditional setting. This page can be found by selecting the “Clinic Tools” tab in the middle of the blue banner atop every Immunize.org web page
In the left-hand column, you will find links to Immunize.org’s web pages:
* Immunize.org: Clinic Tools ([link removed]) main page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed])
* Immunize.org: Clinic Tools: Adolescent Vaccination ([link removed])
* Immunize.org: Clinic Tools: Adult Vaccination ([link removed])
* Immunize.org: Clinic Tools: Documenting Vaccinations ([link removed])
* Immunize.org: Clinic Tools: Scheduling Vaccines ([link removed])
* Immunize.org: Clinic Tools: Screening for Vaccine Contraindications and Precautions ([link removed])
* Immunize.org: Clinic Tools: Storage and Handling ([link removed])
* Immunize.org: Clinic Tools: Vaccination and COVID-19 ([link removed])
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed])
[link removed]
The right-hand column features resources from partners, including CDC’s vaccine recommendations, “General Best Practice Guidelines for Immunization,” and The Epidemiology and Prevention of Vaccine-Preventable Diseases (“The Pink Book”).
Visit the Clinic Tools main page ([link removed]) on Immunize.org.
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is one of our recent citations.
* Washington Post Coronavirus Updates newsletter: Your Questions, Answered ([link removed]) section (7/18/22)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* STAT: WHO Declared Monkeypox Outbreak a Public Health Emergency ([link removed]) (7/23/22)
* ABC: Many Unvaccinated First Responders Distrust Vaccine, Study Says ([link removed]) (7/19/22)
* New York Times: For Monkeypox Patients, Excruciating Symptoms and a Struggle for Care ([link removed]) (7/18/22)
* CNN: India Hits 2 Billion COVID-19 Vaccinations as Infections Hit Four-Month High ([link removed]) (7/17/22)
* New York Times: Sharp Drop in Childhood Vaccinations Threatens Millions of Lives ([link removed]) (7/14/22)
* CNN: Demand for Monkeypox Vaccine Rises with Case Counts, but Supply Remains Low ([link removed]) (7/14/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Recap: These updated Immunize.org educational materials and web pages for clinicians were released during June and July
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials and web pages. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Updated Printable Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (7/8/22)
* Summary of Recommendations for Adult Immunization (age 19 years and older) ([link removed])
* Summary of Recommendations for Child/Teen Immunization (age birth through 18 years) ([link removed])
* Standing Orders for Administering Inactivated Poliovirus Vaccine to Children and Teens ([link removed])
* Standing Orders for Administering Human Papillomavirus Vaccine to Children and Teens ([link removed])
* Emergency Response Worksheet ([link removed])
Immunize.org Updated Web Pages
* Vaccines: COVID-19 ([link removed])
Immunize.org Updated Printable Materials for Patients
* Vaccinations Needed During Pregnancy ([link removed])
* Vaccinations for Adults with Chronic Liver Disease or Infection ([link removed])
* Vaccinations for Adults with Diabetes ([link removed])
* Vaccinations for Adults with Heart Disease ([link removed])
* Vaccinations for Adults with Lung Disease ([link removed])
* Vaccinations for Adults with HIV infection ([link removed])
* Vaccinations for Adults without a Spleen ([link removed])
* Vaccinations for Men Who Have Sex with Men ([link removed])
* Human Papillomavirus (HPV): A Parent’s Guide to Preteen and Teen HPV Vaccination ([link removed])
* Seven translations (Arabic ([link removed]) , Chinese-Simplified ([link removed]) , French ([link removed]) , Korean ([link removed]) , Russian ([link removed]) , Spanish ([link removed]) , and Vietnamese ([link removed]) ) were provided for both of these updated handouts for parents:
+ When Do Children and Teens Need Vaccinations? ([link removed])
+ Vaccinations for Preteens and Teens ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,400 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its nine subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed]) —an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: These new VISs and VIS translations were released during June and July
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
In June, CDC released three VISs:
* Ebola vaccine VIS ([link removed])
* Rabies vaccine VIS ([link removed])
* Smallpox/Monkeypox vaccine VIS ([link removed])
Here are recent VIS translations posted during June and July:
* Hepatitis A vaccine VIS ([link removed]) - Ukrainian
* Hepatitis B vaccine VIS ([link removed]) - Ukrainian
* Influenza (inactive ([link removed]) ) vaccine VIS - Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai
* Influenza (live) ([link removed]) vaccine VIS – Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai
* MMR vaccine VIS - ([link removed]) Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai, Ukrainian
* Polio vaccine VIS ([link removed]) - Ukrainian
* Smallpox/Monkeypox vaccine VIS ([link removed]) - Spanish
* Tdap vaccine VIS ([link removed]) - Armenian, Hindi, Hmong, Japanese, Khmer, Korean, Punjabi, Tagalog, Thai, Ukrainian
* Varicella (chickenpox) vaccine VIS ([link removed]) - Ukrainian
Additionally, two handouts related to VISs were updated:
* Dates of Current Vaccine Information Statements (VISs) ([link removed])
* You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law! ([link removed])
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Novavax COVID-19 Vaccine EUA factsheets for recipients and caregivers are now available in 12 languages
The Novavax COVID-19 Vaccine received Emergency Use Authorization (EUA) from the FDA to provide a two-dose primary series to individuals age 18 and older. The Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Recipients and Caregivers ([link removed]) is now available in 12 languages, courtesy of Oregon Immunization Program. The languages include:
* Arabic ([link removed])
* Chinese – Simplified ([link removed])
* Chinese – Traditional ([link removed])
* Chuukese ([link removed])
* English ([link removed])
* Hmong ([link removed])
* Korean ([link removed])
* Marshallese ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish ([link removed])
* Vietnamese ([link removed])
Related Links
* FDA: Fact Sheet for Healthcare Providers Administering Vaccine: Novavax COVID-19 Vaccine, Adjuvanted ([link removed])
* CDC: Novavax COVID-19, Adjuvanted Vaccine: Overview and Safety ([link removed]) web page (information for the general public)
------------------------------------------------------------
Recognize colleagues and students with Immunize.org's elegantly designed "Vaccines Save Lives" black enamel pins
Immunize.org’s elegantly designed “Vaccines Save Lives” pins ([link removed]) are meaningful gifts for people who care about vaccination. The pin makes a refined statement in hard black enamel with gold lettering and edges, measuring 1.125" x 0.75".
[link removed]
The pin is a stick-through-post variety with the back end covered by a round rubber cap that holds the pin securely. A gold metal spring-lock clasp is also provided.
Wear these pins on clothing, ([link removed]) uniforms, and white coats to show that you value vaccines.
([link removed])
Click here for "Vaccines Save Lives" pin pricing and ordering information. ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022” published in MMWR
CDC published Workplace Perceptions and Experiences Related to COVID-19 Response Efforts among Public Health Workers—Public Health Workforce Interests and Needs Survey, United States, September 2021–January 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
The COVID-19 pandemic has strained many essential frontline professionals, including public health workers....
The 2021 Public Health Workforce Interests and Needs Survey recorded the perspectives of the governmental public health workforce. During March 2020–January 2022, 72% of the workforce fully or partially served in a COVID-19 response role. Apart from funding, 51% of respondents cited a need for additional staff capacity to respond to COVID-19. Approximately 40% of the workforce intends to leave their jobs within the next 5 years....
Purposeful succession planning and focused attention on recruitment and retention that promotes diversity will be critical as the workforce rebuilds while the COVID-19 pandemic evolves.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022” published in MMWR
CDC published Symptoms of Mental Health Conditions and Suicidal Ideation among State, Tribal, Local, and Territorial Public Health Workers—United States, March 14–25, 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
In 2021, state, tribal, local, and territorial (STLT) public health workers reported high levels of symptoms of at least one mental health condition (depression, anxiety, or posttraumatic stress disorder [PTSD])....
In a 2022 survey of 26,069 STLT public health workers, higher PTSD prevalence was associated with more weekly work hours and more time spent on COVID-19 response activities. Most (75.5%) respondents did not think their employer increased mental health support....
To support the mental health of public health workers, public health agencies can modify work-related factors, including making organizational changes for emergency responses and facilitating access to mental health resources and services.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season” published in MMWR
CDC published Influenza Activity and Composition of the 2022–23 Influenza Vaccine—United States, 2021–22 Season ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
CDC collects, compiles, and analyzes data on U.S. influenza activity and viruses....
The severity of the 2021–22 influenza season was low, with two waves of influenza A activity. Influenza activity continued from October 2021 through mid-June 2022, with A(H3N2) viruses predominating throughout the season. This report also describes the composition of the Northern Hemisphere 2022–23 influenza vaccine....
Because of the atypical timing and duration of influenza activity, providers and patients should consider influenza infection as a cause of respiratory illness. Testing for seasonal influenza and monitoring for novel viruses, especially avian A(H5N1) and swine viruses, should continue year-round. Receiving a seasonal influenza vaccine each year remains the best way to protect against seasonal influenza and its potentially severe consequences.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022” published in MMWR
CDC published Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses among Immunocompetent Adults during Periods When SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022 ([link removed]) on July 22 in MMWR. A portion of the summary appears below.
Little is known about COVID-19 vaccine effectiveness (VE) during the Omicron variant BA.2/BA.2.12.2–predominant period or VE of a fourth COVID-19 vaccine dose in persons aged ≥50 years....
VE during the BA.2/BA.2.12.2 period was lower than that during the BA.1 period. A third vaccine dose provided additional protection against moderate and severe COVID-19–associated illness in all age groups, and a fourth dose provided additional protection in eligible adults aged ≥50 years....
Immunocompetent persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19, including a first booster dose for all eligible persons and second dose for adults aged ≥50 years at least 4 months after an initial booster dose. Booster doses should be obtained immediately when persons become eligible.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: HHS, OMH, and CDC offer webinar "Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners" on July 29
As described in detail in today’s Top Stories above, the U.S. Department of Health and Human Services (HHS), Office of Minority Health (OMH), and CDC Office of Minority Health and Health Equity (OMHHE) will host a webinar titled Protecting Our Children and Youth from COVID-19: Information for Parents, Caregivers, and Community Partners ([link removed]) from 1:30–3:00 p.m. (ET) on July 29.
Register for the webinar ([link removed]) . Share this opportunity with interested parents and community members.
For questions about the webinar, please contact CDC’s Office of Minority Health and Health Equity at [email protected] (mailto:[email protected]) .
------------------------------------------------------------
On-demand: CDC’s recorded webinars on principles of vaccination and general best practice guidelines, as well as other segments in “The Pink Book,” now rolling out weekly; CE available
CDC continues its 19-part pre-recorded webinar series ([link removed]) to provide a chapter-by-chapter overview of the 14th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases ([link removed]) (also known as "The Pink Book").
The fourth webinar, on immunization strategies, was released on July 26; no registration is required. Additional webinars will be released weekly, concluding on November 1, 2022.
Information and program details are available on CDC's Pink Book Webinars series ([link removed]) web page.
CME, CNE, CPE, and CEU credits are available for each event. Questions about the material can be submitted to [email protected] (mailto:[email protected]) .
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp